Why It Matters
Globally Protected IP
50+ patents registered across 10+ countries
Designed for Completeness
Targets nerves that lie beyond catheters' reach
Built for Real-World Practice
Simple, intuitive laparoscopic control
Clinically Expandable
A platform with potential in atrial fibrillation and other autonomic indications
About DeepQure
Redefining
Renal Denervation
– And What Comes Next
DeepQure is advancing a new paradigm in hypertension treatment through extravascular renal denervation.
Our lead technology, HyperQure™, is the world’s first laparoscopic RDN system designed to safely deliver complete, circumferential denervation – regardless of anatomical complexity – an area where existing catheter-based solutions fall short.
The system is currently undergoing first-in-human trials in Korea and Early Feasibility Studies in the US, and shows strong potential for patients with resistant hypertension.
Beyond hypertension, we are also exploring applications for other extravascular indications such as atrial fibrillation, with broader autonomic pathways under evaluation.
We're happy to support members of the media
with the latest news about DeepQure and HyperQure.
